Preferred Label : Bladder Cancer Pathway;
NCIt related terms : Bladder cancer;
Alternative definition : KEGG: Bladder cancers arise and progress along two distinctive pathways. The first
of these is often preceded by simple and papillary hyperplasia and exhibits a tumour
morphology that is low-grade, superficial and papillary. Papillary carcinoma has a
tendency to recur locally, but rarely invades and metastasizes. These tumors frequently
show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting
activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes.
The second tumour pathway is characterized by high-grade muscle-invasive tumours,
which either originate from flat carcinoma in situ (CIS)/severe dysplasia or arise
de novo. Over half of these tumours show defects in the tumour suppressors p53 and/or
the retinoblastoma protein (RB) genes and pathways, and over 50% of these tumours
progress to local and distant metastases. Some of the cell cycle-related molecules
show evidence of epigenetic modulation through aberrant promoter hypermethylation
in invasive bladder cancer. Invasion and metastases are promoted by several factors
that alter the tumour microenvironment, including the aberrant expression of E-cadherins
(E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial
growth factor (VEGF).;
KEGG ID : hsa05219;
Origin ID : C91458;
UMLS CUI : C2984270;
Automatic exact mappings (from CISMeF team)
Semantic type(s)
has_gene_product_element
pathway_has_gene_element
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/traitement-intravesical-du-cancer-de-la-vessie.html
2024
Canada
technical report
review of literature
guideline
weights and measures
musculoskeletal rotation, nos
Preventive
Bacillus Calmette-Guerin Antigen
measures
Childhood Bladder Carcinoma
patients
preventive treatment, nos
Epidermolytic Ichthyosis
Patient Reported Outcome Measures
has patient
malignant neoplasm of bladder
BCG
KRT10 wt Allele
Cancer Therapeutic Procedure
BCG
Intravesical
Intravesical Route of Administration
rotation
BCG Vaccine
BCG
urinary bladder cavity
People
urinary bladder cancer
neoplasm, malignant
mycobacterium bovis
persons
Clinical Outcomes Assessment Context of Use
Patient
immunocompromised host
urinary bladder neoplasms
Bladder Cancer Pathway
---
https://www.cochrane.org/fr/CD013774/PROSTATE_limmunotherapie-par-rapport-la-chimiotherapie-pour-le-traitement-du-cancer-de-la-vessie-inoperable
2023
United Kingdom
review of literature
french abstract
urinary bladder cancer
Metastatic Malignant Neoplasm
urinary bladder neoplasms
chemotherapy, nos
chemotherapy
Cancer Immunotherapy
Childhood Bladder Carcinoma
Drug Therapy
albumin/globulin ratio
research report
immunotherapy for cancer
immunotherapy
Bladder Cancer Pathway
Ratio
Cancer Therapeutic Procedure
Succimer
Regulatory Report
malignant neoplasm of bladder
---